VolitionRx (VNRX) Stock Price, News & Analysis

Company Overview

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes. These assays are being evaluated in a range of clinical settings, including colorectal, lung and pancreatic cancer, as well as inflammatory and infectious diseases. Through partnerships with academic research centers, contract research organizations and clinical laboratories, the company is conducting validation studies to support regulatory submissions and commercial adoption across multiple markets.

Headquartered in Belgium, VolitionRx maintains research and development facilities in North America and Asia-Pacific, and has established distribution collaborations in Europe and Southeast Asia. The company was founded in the early 2010s and is listed on the New York Stock Exchange under the ticker symbol VNRX. VolitionRx is led by an experienced management team with backgrounds in molecular diagnostics, life sciences and healthcare commercialization, all dedicated to bringing its blood-based testing platform into routine clinical practice.

Key Stats

• Today's Range: $0.61 to $0.68
• 50-Day Range: $0.60 to $0.78
• 52-Week Range: $0.40 to $0.94
• Volume: 501,831 shs
• Average Volume: 198,353 shs
• Market Capitalization: $73.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Buy

VolitionRx Stock Analysis - MarketRank™

VolitionRx scored higher than 38% of companies evaluated by MarketBeat, and ranked 721st out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

VolitionRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

VolitionRx has a consensus price target of $3.50, representing about 414.7% upside from its current price of $0.68.

Amount of Analyst Coverage

VolitionRx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of VolitionRx is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VolitionRx is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for VNRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VolitionRx does not currently pay a dividend.

Dividend Growth

VolitionRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for VNRX.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

VolitionRx has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for VolitionRx this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for VNRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, VolitionRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,900.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.40% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.09% of the stock of VolitionRx is held by institutions.

VNRX Stock Analysis - Frequently Asked Questions

How have VNRX shares performed this year?

VolitionRx's stock was trading at $0.60 at the beginning of 2025. Since then, VNRX shares have increased by 13.3% and is now trading at $0.68.

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSE:VNRX) posted its quarterly earnings data on Monday, March, 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.50 million.

Who are VolitionRx's major shareholders?

VolitionRx's top institutional investors include Armistice Capital LLC (8.17%), Silverberg Bernstein Capital Management LLC (0.19%), Northwestern Mutual Wealth Management Co. (0.07%) and Blair William & Co. IL (0.04%). Insiders that own company stock include Cameron John Reynolds, Martin Charles Faulkes, Guy Archibald Innes, Jacob Vincent Micallef, Corp Ltd Eight, Gaetan Michel, Salvatore Thomas Butera, Rodney Gerard Rootsaert and Phillip Barnes.
View institutional ownership trends.

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of VolitionRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include BlackRock Innovation and Growth Term Trust (BIGZ), FS KKR Capital (FSK), Guggenheim Strategic Opportunities Fund (GOF), 3M (MMM), OFS Credit (OCCI), XAI Octagon Floating Rate & Alternative Income Trust (XFLT) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 3/25/2024
• Today: 9/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:VNRX
• CIK: 93314
• Web: N/A
• Phone: 646-650-1351
• Fax: 65 32 8172 5651
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for VolitionRx: $3.50
• High Price Target: $5.00
• Low Price Target: $2.50
• Potential Upside/Downside: +414.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.32 million
• Net Margins: -2,321.14%
• Pretax Margin: -2,346.62%
• Return on Equity: N/A
• Return on Assets: -163.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: $1.32 million
• Price / Sales: 55.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.11) per share
• Price / Book: -6.18

Miscellaneous

• Outstanding Shares: 107,595,000
• Free Float: 80,804,000
• Market Cap: $73.16 million
• Optionable: Optionable
• Beta: 1.27